Last updated: July 14, 2026
Executive summary. The case at 1:13-cv-00527 is a federal patent dispute between Novartis Pharmaceuticals Corporation (plaintiff) and Noven Pharmaceuticals Inc. (defendant). Without the underlying docket entries, asserted patent numbers, claims, ANDA/application identifiers, and the procedural posture (dismissals, Markman, injunction rulings, settlement dates), a complete litigation summary and patent-strength analysis cannot be produced accurately.
What patents are asserted in Novartis v. Noven (1:13-cv-00527)?
Answer (required for litigation analysis): Cannot be determined from the provided case identifier alone.
Which Novartis patents are at issue?
- Asserted patent(s), publication numbers, and claim scopes are not available in the input.
- Relief sought (infringement damages vs. injunction) is not available in the input.
Which Noven products and technical facts drive infringement?
- The specific drug product name, strength, formulation, and filing pathway (ANDA/NDA/BLA) are not provided.
- The alleged infringement theory (literal infringement vs. doctrine of equivalents) is not provided.
What is the procedural posture of 1:13-cv-00527?
Answer (required for launch and risk timelines): Cannot be determined from the provided case identifier alone.
Key docket milestones that control exclusivity-to-launch timing
- Complaint filing date and service date: not provided.
- Claim construction (Markman) schedule and rulings: not provided.
- Summary judgment rulings: not provided.
- Trial date or dispositive motions outcome: not provided.
- Judgment (final disposition) or consent decree: not provided.
Does the docket show a settlement agreement?
- Any settlement terms, shared exclusivity, license scope, generic entry date carve-outs, or payment structure are not provided.
What is the infringement and validity argument structure in this case?
Answer (required for patent estate strength): Cannot be determined from the provided case identifier alone.
Infringement positions
- Claim chart structure, construed terms, and accused features are not provided.
Validity positions
- Invalidity grounds (35 USC §§ 102/103/112/101), prior art identifiers, and enablement/indefiniteness outcomes are not provided.
How does Novartis v. Noven affect FDA generic or authorized generic entry risk?
Answer (required for commercial planning): Cannot be determined from the provided case identifier alone.
ANDA/Orange Book linkage
- Which Orange Book listed patents are implicated is not provided.
- Whether this is a Paragraph IV dispute and which patents were the basis for any notice letter is not provided.
Launch timing triggers
- Whether any court-ordered injunction was issued and stayed is not provided.
- Whether any “carve-out” design-around was permitted is not provided.
What did the court decide in 1:13-cv-00527?
Answer (required for litigation summary): Cannot be determined from the provided case identifier alone.
Injunction, damages, and claim scope outcomes
- No record of findings, final judgment, or remedial orders is provided.
What is the strength of the asserted Novartis patent estate based on this litigation?
Answer (required for licensing and investment decisions): Cannot be determined from the provided case identifier alone.
Patent survivability signals
- Patent claims that survived claim construction or summary judgment are not provided.
- Any final invalidity ruling or narrowing construction that would drive non-infringement is not provided.
Which companies are involved beyond the named parties?
Answer (required for settlement and manufacturing/IP barriers): Cannot be determined from the provided case identifier alone.
Potential additional participants
- Manufacturers, co-defendants, generic filers, or downstream distributors are not provided.
Comparison: how does this case’s posture compare to other similar Novartis v. generic disputes?
Answer (required for competitive landscape): Cannot be determined from the provided case identifier alone.
Analog cases and patterns
- No other matter identifiers, dates, or outcomes are provided.
Key Takeaways
- The case identifier 1:13-cv-00527 alone is insufficient to generate a litigation summary that is complete and accurate.
- A litigation summary for professional use requires docket-level facts: asserted patent numbers, FDA application linkage, procedural rulings, and final disposition. None of these are included in the prompt.
FAQs
- What is the docket disposition for Novartis v. Noven, 1:13-cv-00527?
- Which Orange Book patents were asserted in Novartis v. Noven (1:13-cv-00527)?
- Was the dispute an ANDA Paragraph IV case, and what FDA application was involved?
- Did the court issue an injunction or stay, and what were the conditions?
- Did the parties enter into a settlement affecting generic launch dates?
References
- No sources were provided with the case identifier 1:13-cv-00527, and no cited materials are available to compile an APA reference list.
